[Virtual Event] 3rd Annual Summit on Controlled Substances – Regulation, Litigation, and Enforcement - July 21st-22nd, 9:00 am-4:30 pm EDT

American Conference Institute (ACI)
Contact

Date: July 21-22, 2020

TO REGISTER, CLICK HERE » - Or call 888-224-2480 for fastest service.

You can save an extra 10% off the current rate by using code D10-999-JDS20.

Be part of one-of-a-kind, interactive virtual conference where stakeholders can gather with peers, discuss challenges, and walk away with tailored strategies for overcoming these challenges.

As our nation continues with attempts to combat the opioid overdose crisis, the regulations and requirements for stakeholders along the entire supply chain continue to evolve at a rapid pace. Recently the DOJ exercised its authority to reduce opioid production and DEA modified its opioid distribution quota rules in an attempt to minimize diversion. Further, state, city, and county litigations continue to escalate, with no end in sight.

EXCLUSIVE KEYNOTES FROM DEA, DOJ AND FDA ON ENFORCEMENT INITIATIVES

Claire M. Brennan

Section Chief – Liaison Diversion Control Division
U.S. Drug Enforcement Administration

Scott A. Brinks

Section Chief Regulatory Drafting & Policy Support Section Diversion Control Division
U.S. Drug Enforcement Administration

Dominic Chiapperino, Ph.D.

Director, Controlled Substance Staff, Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Gustav Eyler

Director, Consumer Protection Branch
U.S. Department of Justice


Click here to see the complete list of speakers »

Our faculty consisting of current and former DEA officials, DOJ representatives, in-house industry counsel, and outside counsel, will provide an up-to-date analysis of the current regulations, best practices for staying compliant, avoiding DEA investigations, and knowing how to respond when DEA comes knocking at your door.

INDUSTRY THOUGHT LEADERS WILL HELP YOU

  • ANALYZE the implications of the proposed MDL settlement and the probability of a global settlement
  • ASSESS the therapeutic potential of cannabinoids
  • EVALUATE incentives for new medicines to treat pain and addiction
  • DEVELOP a comprehensive controlled substances compliance program

REGISTER NOW and save an extra 10% off the conference by using code D10-999-JDS20.

*Discount is valid for new registration only and it’s not applicable for workshops.

Written by:

American Conference Institute (ACI)
Contact
more
less

American Conference Institute (ACI) on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.